DNA damage induced by cis- and carboplatin as indicator for in vitro sensitivity of ovarian carcinowma cells

BMC Cancer

Volumn 9, Issue , 2009, Pages 359-

  Unger, Florian T ^a   Klasen, Hermann A ^b   Tchartchian, Garri ^b   de Wilde, Rudy L ^b   Witte, Irene ^a  

^a UNIVERSITY OF OLDENBURG   (Germany)

^b PIUS HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOMEDAC; CARBOPLATIN; CISPLATIN; DNA; DOXORUBICIN; FLUORESCEIN DIACETATE; GEMCITABINE; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; CANCER CELL CULTURE; CELL COUNT; CELL ISOLATION; CELL VIABILITY; CHEMOSENSITIVITY; COMET ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; FEMALE; HUMAN; HUMAN CELL; HYDROLYSIS; IN VITRO STUDY; INCUBATION TIME; OVARY CARCINOMA; SENSITIVITY ANALYSIS; TUMOR BIOPSY;

EID: 70449698170     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-359     Document Type: Article

References (37)

1. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinacting agents. Cancer Treatment Rev 2007, 33:9-23.
2. Gonzalez VM, Fuertes MA, Alonso C, Perez JM. Is cisplatin-induced cell death always produced by apoptosis?. Mol Pharmacol 2001, 59:657-663.
3. Reed E, Ozols RF, Tarone R, Yuspa SH, Poirier MC. Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. Proc Natl Acad Sci USA 1987, 84:5024-5028. 10.1073/pnas.84.14.5024, 305239, 3110781.
4. Angelis KJ, Dusinská M, Collins AR. Single cell gel electrophoresis: detection of DNA damage at different levels of sensitivity. Electrophoresis 1999, 20:2133-8. 10.1002/(SICI)1522-2683(19990701)20:10<2133::AID-ELPS2133>3.0.CO;2-Q, 10451126.
5. Collins AR. The comet assay for DNA damage and repair: principles, applications, and limitations. Mol Biotechnol 2004, 26:249-61. 10.1385/MB:26:3:249, 15004294.
6. Pfuhler S, Wolf HU. Detection of DNA-crosslinking agents with the alkaline comet assay. Environm Mol Mutagenesis 1996, 27:196-201.
7. Cemazar M, Pipan Z, Grabner S, Bukovec N, Sersa G. Cytotoxicity of different platinum (II) analogues to human tumour cell lines in vitro and murine tumour in vivo alone or combined with electroporation. Anticancer Res 2006, 26(3A):1997-2002.
8. Sharma S, Neale MH, Di Nicolantonio F, Knight LA, Whitehouse PA, Mercer SJ, Higgins BR, Lamont A, Osborne R, Hindley AC, Kurbacher CM, Cree IA. Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma. BMC Cancer 2003, 3(3):19. 10.1186/1471-2407-3-19, 166157, 12841853.
9. Larsson R, Kristensen J, Sandberg C, Nygren P. Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukaemia, using a fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer 1992, 50:177-185. 10.1002/ijc.2910500204, 1730510.
10. von Heideman A, Sandstrom M, Csoka K, Tholander B, Larsson R, Bergh J, Nygren P. Evaluation of drug interactions in the established FEC regimen in primary cultures of tumour cells from patients. Annals of Oncology 2000, 11:1301-1307. 10.1023/A:1008332816407, 11106120.
11. Kurbacher CM, Cree IA, Bruckner HW, Brenne U, Kurbacher JA, Muller K, Ackermann T, Gilster TJ, Wilhelm LM, Engel H, Mallmann PK, Andreotti PE. Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer. Anticancer Drugs 1998, 9:51-57. 10.1097/00001813-199801000-00006, 9491792.
12. Frost BM, Nygren P, Gustafsson G, Forestier E, Jonsson OG, Kanerva J, Nygaard R, Schmiegelow K, Larsson R, Lönnerholm G, . Nordic Society for Paediatric Haematology and Oncology Increased in vitro cellular drug resistance is related to poor outcome in high-risk childhood acute lymphoblastic leukaemia. British journal of haematology 2003, 122:376-385. 10.1046/j.1365-2141.2003.04442.x, 12877664.
13. Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999, 57:27-741. 10.1016/S0006-2952(98)00307-4, 9920282.
14. Lorusso D, Ferrandina G, Fruscella E, Marini L, Adamo V, Scambia G. Gemcitabine in epithelial ovarian cancer treatment: current role and future perspectives. Int J Gynecol Cancer 2005, 15:1002-1013. 10.1111/j.1525-1438.2005.00331.x, 16343176.
15. Rotman B, Papermaster BW. Membrane properties of living mammalian cells as studied by enzymatic hydrolysis of fluorogenic esters. Proc Natl Acad Sci USA 1996, 55:134-141.
16. Tice RR, Agurell E, Anderson D, Burlinson B, Hartmann A, Kobayashi H, Miyamae Y, Rojas E, Ryu JC, Sasaki YF. Single cell gel/Comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen 2000, 35:206-221. 10.1002/(SICI)1098-2280(2000)35:3<206::AID-EM8>3.0.CO;2-J, 10737956.
17. Sargent JM. The use of the MTT assay to study drug resistance in fresh tumour samples. Recent Results. Cancer Res 2003, 161:13-25.
18. Taylor CG, Sargent JM, Elgie AW, Williamson CJ, Lewandowicz GM, Chappatte O, Hill JG. Chemosensitivity testing predicts survival in ovarian cancer. Eur J Gynaecol Oncol 2001, 22:278-282.
19. Komatsu M. Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers. Mol Cancer Therapy 2006, 5(3):767-775.
20. Hsu DS, Balakumaran BS, Acharya CS, Vlahovic V, Walters KS, Garman K, Anders C, Riedel RF, Lancaster J, Harpole D, Dressman HK, Nevins JR, Febbo PG, Potti A. Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistent patients with advanced cancer. J Clin Oncol 2007, 25:4350-4357. 10.1200/JCO.2007.11.0593, 17906199.
21. Yan X. Identification of Platinum-Resistance Associated Proteins through Proteomic Analysis of Human Ovarian Cancer Cells and their Platinum-Resistant Sublines. J Proteome Res 2007, 6:772-780. 10.1021/pr060402r, 17269733.
22. Kurbacher CM, Cree IA. Chemosensitivity testing using microplate adenosine triphosphate-based luminescence measurements. Meth Mol Med 2005, 110:101-20.
23. Martelli L. Different accumulation of cisplatin, oxaliplatin and JM216 in sensitive and cisplatin-resistent human cervical tumour cells. Biochem Pharmacol 2006, 72:693-700. 10.1016/j.bcp.2006.06.008, 16844093.
24. Fanning J, Biddle WC, Goldrosen M, Crickard K, Crickard U, Piver MS, Foon KA. Comparison of cisplatin and carboplatin cytotoxicity in human ovarian cancer cell lines using the MTT assay. Gynecol Oncol 1990, 39:119-122. 10.1016/0090-8258(90)90416-I, 1699853.
25. Hartmann A, Speit G. The contribution of cytotoxicity to DNA-effects in the single cell gel test (Comet assay). Toxicol Lett 1996, 90:183-188.
26. Henderson L, Wolfreys A, Fedyk J, Bourner C, Windebank S. The ability of the Comet assay to discriminate between genotoxins and cytotoxins. Mutagenesis 1998, 13:89-94. 10.1093/mutage/13.1.89, 9491401.
27. Stewart DJ. Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol 2007, 63:12-31. 10.1016/j.critrevonc.2007.02.001, 17336087.
28. Muggia F. Platinum compounds 30 years after the introduction of cisplatin: Implications for the treatment of ovarian cancer. Gynecol Oncol 2009, 112(1):275-281. 10.1016/j.ygyno.2008.09.034, 18977023.
29. Nakayama K, Kanzaki A, Ogawa K, Miyazaki K, Neamati N, Takebayashi Y. Copper-transporting P-type adenosine triphosphatase (ATP7B) as a cisplatin based chemoresistance marker in ovarian carcinoma: comparative analysis with expression of MDR1, MRP1, MRP2, LRP and BCRP. Int J Cancer 2002, 101:488-495. 10.1002/ijc.10608, 12216079.
30. Yakirevich E, Sabo E, Naroditsky I, Sova Y, Lavie O, Resnick MB. Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas. Gynecol Oncol 2006, 100:152-159. 10.1016/j.ygyno.2005.08.050, 16198399.
31. Satoh T, Nishida M, Tsunoda H, Kubo T. Expression of glutathione S-transferase pi (GST-pi) in human malignant ovarian tumors. Eur J Obstet Gynecol Reprod Biol 2001, 96:202-208. 10.1016/S0301-2115(00)00473-5, 11384808.
32. Mayr D, Pannekamp U, Baretton GB, Gropp M, Meier W, Flens MJ, Scheper R, Diebold J. Immunohistochemical analysis of drug resistance-associated proteins in ovarian carcinomas. Pathol Res Pract 2000, 196(7):469-75.
33. Surowiak P, Materna V, Kaplenko I, Spaczyñski M, Dietel M, Lage H, Zabel M. Augmented expression of metallothionein and glutathione S-transferase pi as unfavourable prognostic factors in cisplatin-treated ovarian cancer patients. Virchows Arch 2005, 447(3):626-33. 10.1007/s00428-005-1228-0, 15968547.
34. Mizutania H, Tada-Oikawaa S, Hirakua Y, Kojimab M, Kawanishia S. Mechanism of apoptosis induced by doxorubicin through the generation of hydrogen peroxide. Life Sci 2005, 76:1439-1453. 10.1016/j.lfs.2004.05.040, 15680309.
35. Powis G. Toxicity of free radical forming anticancer drugs. "The Toxicology of Anticancer Drugs" 1991, 106-132. New York: Pergamon Press, Powis G, Hacker MP.
36. Lown JW, Chen HH, Plambeck JA, Acton EM. Further studies on the generation of reactive oxygen species from activated anthracyclines and the relationship to cytotoxic action and cardiotoxic effects. Biochem Pharmacol 1982, 31:575-581. 10.1016/0006-2952(82)90162-9, 6279110.
37. Plunkett W, Huang P, Searcy CE, Gandhi V. Gemcitabine: Pharmacology and mechanisms of action. Sem Oncol 1996, 23(5 suppl 10):3-15.